• Plus Therapeutics began manufacturing activities with SpectronRx under a previously executed master services agreement to support GMP pivotal-trial readiness for REYOBIQ.
• SpectronRx will serve as a second GMP manufacturing site alongside Radiomedix, with Rhenium-186 isotope supply sourced through Telix Pharmaceuticals.
• Technology transfer to SpectronRx covers REYOBIQ manufacturing process, Rhenium-186 processing, analytical methods.
• SpectronRx facility in Indiana will provide on-demand production for both Rhenium-186 and REYOBIQ in one site to streamline logistics.
• Plus is targeting completion of manufacturing scale-up for late-stage clinical supply needs in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604230730PRIMZONEFULLFEED9695243) on April 23, 2026, and is solely responsible for the information contained therein.